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Abstract
Background: Mature carotid plaques are complex structures, and their histological classification is challenging. The
carotid plaques of asymptomatic and symptomatic patients could exhibit identical histological components.
Objectives: To investigate whether matrix metalloproteinase 9 (MMP-9), tissue inhibitor of MMP (TIMP), and
cyclooxygenase-2 (COX-2) have different expression levels in advanced symptomatic carotid plaques, asymptomatic
carotid plaques, and normal tissue.
Methods: Thirty patients admitted for carotid endarterectomy were selected. Each patient was assigned
preoperatively to one of two groups: group I consisted of symptomatic patients (n = 16, 12 males, mean age 66.7
± 6.8 years), and group II consisted of asymptomatic patients (n = 14, 8 males, mean age 67.6 ± 6.81 years). Nine
normal carotid arteries were used as control. Tissue specimens were analyzed for fibromuscular, lipid and calcium
contents. The expressions of MMP-9, TIMP-1 and COX-2 in each plaque were quantified.
Results: Fifty-eight percent of all carotid plaques were classified as Type VI according to the American Heart
Association Committee on Vascular Lesions. The control carotid arteries all were classified as Type III. The median
percentage of fibromuscular tissue was significantly greater in group II compared to group I (p < 0.05). The median
percentage of lipid tissue had a tendency to be greater in group I than in group II (p = 0.057). The percentages of
calcification were similar among the two groups. MMP-9 protein expression levels were significantly higher in
group II and in the control group when compared with group I (p < 0.001). TIMP-1 expression levels were
significantly higher in the control group and in group II when compared to group I, with statistical difference
between control group and group I (p = 0.010). COX-2 expression levels did not differ among groups. There was
no statistical correlation between MMP-9, COX-2, and TIMP-1 levels and fibrous tissue.
Conclusions: MMP-9 and TIMP-1 are present in all stages of atherosclerotic plaque progression, from normal tissue
to advanced lesions. When sections of a plaque are analyzed without preselection, MMP-9 concentration is higher
in normal tissues and asymptomatic surgical specimens than in symptomatic specimens, and TIMP-1 concentration
is higher in normal tissue than in symptomatic specimens.
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Background
The complex structures of mature carotid plaques com-
plicates their histological classification. Patients may
exhibit the same carotid plaque histological components
whether they are symptomatic or asymptomatic. Fibrotic
and calcific plaques could become vulnerable, where as
complex plaques with surface defects, hemorrhage, and
thrombus could remain silent [1,2]. At present, it is not
possible to predict whether a carotid plaque will become
symptomatic or when symptoms will occur [3]. The nat-
ural history of plaque progression and destabilization is
unknown, but it has been suggested that progression of
atherosclerosis is a summation of sequential repetitive
events resulting in plaque stabilization and plaque desta-
bilization [4]. Carotid atherosclerotic plaque remodeling
and an increased risk of symptomatic plaque rupture
seem to be partially mediated by matrix metalloprotei-
nases (MMPs). Overexpression of active MMPs contri-
butes to the dissolution of collagenous matrix in the
fibrous cap, causing structure to weaken and become
brittle and more susceptible to rupture when exposed to
hemodynamic stress [5-7]. The expression of 72-kDA
(MMP-2) and 92-kDa (MMP-9) gelatinase has been
demonstrated within human atherosclerotic lesions and
is implicated in plaque rupture and, consequently, in
acute ischemic events [8,9]. However, previous reports
have failed to detect a positive correlation between
MMP-9 and symptomatic plaques. Instead, the level of
MMP-9 appears to be related to the age of the patient
and the quantity of fibrous tissue in the plaque
[5,10-12]. Expression of the tissue inhibitor of MMP
(TIMP) is related to plaque stabilization and is increased
in calcified areas of carotid plaques [8]. Cyclooxygenase - 2
(COX-2) is involved in MMP production by monocytes
[13,14]. We conducted this study to investigate whether
MMP-9, TIMP-1, and COX-2 have different expression
levels in advanced symptomatic versus asymptomatic
carotid plaques removed from surgical patients and
in normal tissue in carotid arteries removed from
cadavers.
Methods
A. Patients
Thirty-six nonconsecutive surgical inpatients admitted
for carotid endarterectomy for extracranial high-grade
(3 70%) internal carotid artery stenosis were selected for
this study. Local ethical committee approval was
obtained for the study and for procurement of speci-
mens. Written informed consent was obtained from all
patients. Exclusion criteria were: (1) a disorder that
could seriously complicate surgery (3 patients); (2) term-
inal cancer (1 patient); and (3) patient refusal of opera-
tion (2 patients). The study was conducted on 30
common or internal carotid artery plaques from the 30
remaining patients (21 males, mean age 68.03 ± 7.3
years). A clinical examination was performed that
included a neurological exam to establish the number
and duration of ischemic events. The time elapsed
between the last symptom and the surgery was recorded
for each patient. Before surgery, all patients underwent
the following: (1) either cerebral angiography or mag-
netic resonance angiography with Duplex ultrasound for
grading carotid artery stenosis and assessment of the
intracranial arterial system; and (2) either computed
tomography (CT) or magnetic resonance imaging (MRI)
of the brain. The presence or absence of infarction in
the corresponding middle cerebral artery territory was
noted. Focal cerebral ischemic events were defined as
transient ischemic attack (TIA), amaurosis fugax (AF),
central retinal artery occlusion, or cerebrovascular acci-
dent. Patients were considered to be symptomatic if
they had experienced AF, TIA, or stroke ipsilateral to
the carotid lesion being studied. Silent infarcts and lacu-
nar symptomatology, diagnosed by a neurologist based
on clinical and brain CT and/or MRI located ipsilateral
to the stenosis, were also considered symptomatic. Con-
versely, patients without any history of recent neurologic
symptoms or with nonspecific, nonhemispheric symp-
toms such as dizziness and vertigo were considered
asymptomatic. Among asymptomatic patients with ste-
nosis >70%, the indication of surgical therapy depended
on comorbidity and vertebro-basilar (in)sufficiency. Each
patient was assigned preoperatively to one of two groups
on the basis of their symptoms: group I consisted of
symptomatic patients (n = 16, 12 males, mean age 66.7
± 6.8 years), and group II consisted of asymptomatic
patients (n = 14, 8 males, mean age 67.6 ± 6.81 years).
At the baseline examination, height, weight, body mass
index, blood pressure, fasting serum total cholesterol,
high density lipoprotein cholesterol, low density lipopro-
tein cholesterol, triglycerides, fasting plasma glucose,
electrocardiograms, and information regarding coronary
artery disease, diabetes mellitus, and smoking habits
were obtained from each patient. Percentages of carotid
diameter reduction, procedural surgical methods, conco-
mitant therapy, age, sex, and risk factors did not differ
substantially among the two groups (Table 1). Nine car-
otid arteries were removed from human adult cadavers
that had not been preselected for carotid artery disease.
These specimens lacked any macroscopic signs of ather-
osclerotic plaques and were used as controls.
B. Tissue specimens and histological analyses
Carotid plaques were obtained immediately after endar-
terectomy. All surgeries were performed using standard
surgical techniques and with minimal manipulation of
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the specimen. No attempts were made to evaluate the
presence and the degree of surface ulceration or throm-
bus. All plaques were removed en bloc, without frag-
mentation or significant distortion. After removal, the
plaque section to be used for histological analysis was
placed in fresh 4% paraformaldehyde solution and par-
tially decalcified overnight for subsequent sectioning.
The samples were transected transversely at 3-4 mm
and embedded in paraffin. For most of the specimens,
five or six blocks were available. Histological analysis
was performed based on American Heart Association
(AHA) classification system for human atherosclerotic
lesions [15,16]. Tissue specimens also were analyzed for
lipid, fibrous tissue, and calcium. Results for each tissue
component were expressed as a percentage of the total
plaque area obtained as described previously [10,11].
Picro sirius red staining of collagen and fat was visua-
lized using polarized light, smooth muscle cells (SMC)
were labeled with alpha actin, and calcifications and fat
were haematoxylin eosin stained. For tissue characteriza-
tion a video camera (Leica Microsystems, Bannockburn,
IL, US) was applied to a Leica microscope DMR (Leica
Microsystems) and attached to a computer. The images
were processed using Leica QWin software (Leica
Microsystems Image Solutions, Cambridge, UK). Sec-
tions to be used for MMP-9, TIMP-1, and COX-2 quan-
tification were snap-frozen in liquid nitrogen and stored
at -70°C until processing. The human carotid arteries
removed from cadavers received identical treatment.
C. Immunoblotting
The protein expression levels of MMP-9, TIMP-1, and
COX-2 in tissue extracts were analyzed by immunoblot-
ting following SDS-PAGE. Specific regions of each pla-
que were not preselected for this analysis. Briefly,
carotid samples (n = 44) were minced and homogenized
in lysis buffer containing PBS (pH 7.2), 0.5% Triton X-
100, 0.1% SDS, 0.5% sodium deoxycholate, and protease
inhibitor cocktail (Roche) at 4°C. The extracts were
centrifuged (5000 rpm, 15 min, 4°C), and supernatants
were collected and frozen at
-20°C until analysis. Total protein concentrations in the
lysates were determined using the Bradford method. Pro-
teins (10 μg) were separated through a 10% acrylamide/
bisacrylamide SDS gel and transferred to a nitrocellulose
membrane. After incubation in nonfat milk, membranes
were probed with anti-MMP (1:1000), anti-COX-2
(1:250), or anti-TIMP-1 (1: 50) antibodies (Santa Cruz
Biotechnology), followed by incubation in secondary anti-
bodies conjugated to horseradish peroxidase (HRP).
Reactions were developed using WestPico (Pierce, Rock-
ford, IL, US). As an endogenous control, membranes
were probed with anti-b actin (1:5000; Sigma-Aldrich, St.
Louis, MO, US) and anti-mouse IgG conjugated to HRP
(KLP 1:2000; Kirkegaard and Perry Laboratories,
Gaithersburg, MD, US). Densitometry analysis was per-
formed using ImageJ software.
Statistical analysis
Categorical variables were expressed as percentages, and
continuous variables were expressed as means ± SD and
medians. The Shapiro-Wilk test was used to evaluate
sample normality. For quantitative parameters, the
Mann-Whitney nonparametric test was used to compare
groups. The Spearman coefficient was used to identify
correlations between quantitative variables. Statistical
significance was indicated by a value of p < 0.05.
Analyses were performed using Statistica v. 8.0.
Results
A. Histological analysis
Fifty-eight percent of all carotid plaques were classified
as Type VI according to the AHA classification system
(i.e., complex plaque with possible surface defect,
hemorrhage, or thrombus; Table 2). All carotid arteries
removed from human cadavers were classified as Type III
(i.e., preatheroma with extracellular lipid pools; Table 2).
The percentages of lipid, fibromuscular tissue, and cal-
cium were determined for each plaque section (Table 3).
The median percentage of fibromuscular tissue was
significantly greater in group II (75.9% ± 3.6) than
in group I (60.4% ± 5.4; p < 0.05). The median percentage
of lipid tissue in group I (32.3% ± 4.7) exhibit a
Table 2 AHA classification of atherosclerotic lesions
across clinical groups
AHA Type Group I (n = 16) Group II (n = 14)
Type IV (n) 2 0
Type V (n) 4 2
Type VI (n) 7 11
Type VII (n) 2 0
Type VIII (n) 1 1
Table 1 Patient baseline characteristics
Group I (n = 16) Group II (n = 14)
Age, years 66.7 ± 6.8 67.6 ± 6.8
Sex, M/F 12/4 8/6
Hypertension 10 1
Diabetes Mellitus 2 3
Active smoking 3 3
Hypercholesterolemia 2 1
CAD 4 0
Aspirin 15 10
Statin 5 4
ACE inhibitors 9 8
Ticlopidine 4 1
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nonsignificant tendency to be greater than group II (19.5
± 3.2, p = 0.057). The percentage of calcium did not dif-
fer significantly between groups (Table 3). The control
group had no fibromuscular tissue, lipid tissue, or
calcium.
B. Expression of MMP-9, COX-2, and TIMP-1
MMP-9 expression was significantly elevated in group II
and in the control group when compared to group I (p
< 0.001; Table 4). COX-2 did not differ significantly
across groups. TIMP-1 levels were significantly higher
in the control group and in group II than in group I,
with statistical difference between control group and
group I (p = 0.01; Table 4). No statistical correlation
was detected between MMP-9, COX-2, and TIMP-1
levels and fibrous tissue (data not shown).
Discussion
The carotid plaques examined in the present study were
obtained from highly stenotic lesions presumably repre-
senting the final stage of plaque development and desta-
bilization. We verified that all surgical specimens had a
high grade of complexity. This highlights the challenge
of trying to separate vulnerable from stable carotid pla-
ques based only on histological analysis. Lesions consid-
ered advanced by their histology may or may not
narrow the arterial lumen, may or may not be visible by
angiography, and may or may not produce clinical man-
ifestations [15]. The AHA classification for human
atherosclerotic lesions considers the presence or absence
of different tissue components in plaques but does not
account for the proportion of each component. There-
fore, the classification of vulnerable or asymptomatic
plaques is based on patients’ symptoms. When histolo-
gic analysis is used to classify plaques as vulnerable or
asymptomatic, specific regions inside plaques (e.g., the
plaque shoulder) are assessed. Several reports suggest
that vulnerability to plaque rupture is a multifocal phe-
nomenon, particularly at the time of acute presentation.
However, the imbalanced degradation and synthesis of
the extracellular matrix persists in advanced lesions, par-
ticularly in plaques with disruption [17]. The mechan-
isms linking MMP-9 expression within plaques and
atherosclerosis still are speculative and maybe explained
as an epiphenomenon of the increased number of
macrophages within vulnerable plaques [18]. However,
plaques from MMP-9 knockout mice are associated
with a lower macrophage content compared with those
of wild type mice [19], suggesting a primary role of
MMP-9 in macrophage migration and activity. Macro-
phages have a pivotal role in the transition between
inflammation and repair; they participate in the wound-
healing process via matrix degradation, neovasculariza-
tion, and recruitment and proliferation of fibroblasts.
From a group of 526 symptomatic patients, Redgrave
et al. [20] observed a strong correlation between macro-
phage infiltration and plaque stability. These researches
also reported a tendency for plaque inflammation and
overall instability to persist with time after TIA but to
decrease with time after stroke. The percentage of
macrophage area and the percentage of MMP-9 area are
markers of plaque instability [21-23]. Kunte et al [24],
assessing symptomatic patients with stroke or TIA,
found a higher median content of T cells/mm2 and
higher median total percentages of macrophage area and
MMP-9 area in patients with thromboembolic cerebral
ischemia when compared with patients with hemody-
namic stroke. They analyzed the tissue specimens in
sections with selection of specific regions close to the
lipid core in the shoulder region of the plaque. In the
present study, we did not assess macrophage, T-lympho-
cyte infiltration, nor did we select specific sites of exten-
sive inflammation to measure MMP-9, TIMP-1, and
COX-2 expressions levels. We verified that MMP-9 is
expressed at all stages of atherosclerotic lesions, from
normal tissue to advanced plaques. When the plaque
was analysed as a whole, rather than specifically in areas
of hemorrhage or thrombosis, high concentrations of
MMP-9 were detected in normal tissues and in asymp-
tomatic surgical specimens. Peeters et al [23], studying
MMP-2, MMP-8, and MMP-9 levels in 804 sympto-
matic and 174 asymptomatic patients, determined that
MMP-levels did not change following stroke except for
Table 3 Representation of fibromuscular tissue, lipid, and
calcification in plaques across clinical groups
(median ± sd)
Group I
(16)
Group II
(14)
p
Histological Fibromuscular tissue
(%)
60.4 ± 5.4 75.9 ± 3.6 0.047
Parameters Lipid (%) 32.3 ± 4.7 19.5 ± 3.2 0.057
Calcification (%) 7.3 ± 2 4.5 ± 2.3 0.383
Table 4 MMP-9, COX-2, and TIMP-1 expression
(in arbitrary units of band densitometry, normalized
by b-actin expression), across the groups
Variable Group Mean Median SD p value
MMP-9 GI 127 147 44.3
GII 198.9 201.3 11.5
Control 182.1 181 25.2 <0.001
COX-2 GI 2.7 2.3 1.6
GII 3.3 2.7 1.8
Control 2.9 2.1 2.1 0.739
TIMP-1 GI 1.2 0 1.8
GII 2.1 2.1 1.8
Control 3.6 2.4 2.7 0.039
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the normal decrease in macrophage infiltration with
time. These investigators suggested that MMPs also can
be produced by other cell types such as SMC, which
tended to increase with time after stroke, thereby balan-
cing the macrophage-related effects on MMP levels.
Furthermore, it has been suggested that MMPs are asso-
ciated with SMC migration, suggesting that gelatinases
play a role in lesion stabilization [25]. In the present
study, we classified the patients according to the pre-
sence of symptoms and did not differentiate between
TIA or stroke or the mechanisms of cerebral ischemia.
In addition, we did not quantify SMC. Another impor-
tant aspect of plaque vulnerability is the plasma concen-
tration of MMP-9. In a study analyzing the MMP-9
activity in asymptomatic patients’ plaques, Turu et al.
[26] reported that increased plaque activity was corre-
lated with a lower MMP-9 plasma level. This may sug-
gest that circulating MMP-9 levels do not only result
from the coexistence of brain ischemic lesions, but in
asymptomatic patients, MMP-9 may be also important
in atherogenesis. We did not determine the plasma level
of MMP-9 in the present study; however, we tried to
identify more inflammatory activity by measuring COX-
2 expression within plaques. Cipollone et al [8] sug-
gested that synthesis of COX-2 and prostaglandin E
synthase (PGES) by activated macrophages is associated
with acute ischemic syndromes, possibly through MMP-
induced plaque rupture. Higher expression levels of
COX-2, PGES, MMP-2, and MMP-9 were detected in
specimens obtained from the carotid lesions of patients
with recent TIA or stroke compared with specimens
obtained from asymptomatic patients. Specimens were
preselected for plaque ulceration and intraplaque hemor-
rhage before analysis. Because we did not preselect speci-
mens for suspicious areas, and instead analyzed all
sections of the plaque, we could not detect any correla-
tion between COX-2, MMP-9, and TIMP-1expression
and patients’ symptoms. Finally, immunocytochemical
studies suggest that nondiseased human arteries and
experimental animal arteries uniformly express MMP-2
and the inhibitory TIMP-1 and TIMP-2 [27]. The present
study corroborates these findings because we observed a
high concentration of MMP-9 and TIMP-1 in normal
human arteries. Future studies should focus on the
genetic variants of MMPs and features of the athero-
sclerotic plaques that could lend insight into the mechan-
ism by which MMPs, ultimately, influence plaque
structure and vulnerability [28].
Conclusions
MMP-9 and TIMP-1 are present in all stages of athero-
sclerotic plaque progression, from normal tissue to
advanced lesions. When no preselected region of a pla-
que is analyzed, the MMP-9 concentration is higher in
normal tissues and in asymptomatic surgical specimens,
suggesting that MMP-9 is part of the atherogenesis pro-
cess and is not specifically a factor in acute disruption
events. TIMP-1 expression levels were higher in normal
tissues and in asymptomatic specimens than in sympto-
matic specimens. COX-2 concentrations did not differ
among groups. The quantification of macrophages and
SMC should be a focus in future studies.
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